Hong Kong
Industry
BMI View: Attention deficit hyperactivity disorder (ADHD) represents a small but growing opportunity for pharmaceutical companies operating in South East Asia. The prevalence of the...
2011-05-04Economy
Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer...
2010-09-28Industry
Hypertension is major problem in China. The cardiovascular disease affects approximately 200mn individuals and places a significant burden on society. Diagnosis rates are low and...
2010-03-16Industry
Hong Kong's negative pharmaceutical trade balance is forecast to widen over the next five years. The main drivers are increased imports of affordable generic medicines from mainland...
2010-02-09Industry
Health expenditure in Hong Kong is expected to increase from HKD80.22bn (US$10.34bn) in 2009 to HKD83.19bn (US$10.69bn) in 2010 - a rise of 3.7% in local currency terms and 3.4% in...
2010-02-04Industry
A series of product scandals in early 2009 have shown Hong Kong's pharmaceutical regulations to be below international standards. The country's Pharmaceutical Service of the Department...
2010-01-07Industry
BMI's April 2009 prediction that pharmaceutical regulations in Hong Kong would be tightened has proved correct.[1] The Review Committee on Regulation of Pharmaceutical Products has...
2009-11-03Industry
Public confidence in Hong Kong's pharmaceutical supply chain has been shattered. A series of scandals exposed deficiencies in numerous links, including manufacturers, wholesalers,...
2009-04-01
